,address1,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,3940 Trust Way,Hayward,CA,94545,United States,510 780 0819,https://benitec.com,Biotechnology,Healthcare,"Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.",18,"{'maxAge': 1, 'name': 'Dr. Jerel A. Banks M.D., Ph.D.', 'age': 47, 'title': 'Exec. Chairman & CEO', 'yearBorn': 1975, 'fiscalYear': 2023, 'totalPay': 575068, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,2.91,2.96,2.96,3.17,2.91,2.96,2.96,3.17,0.0,1.018672,-0.1962733,38245,38245,804526,47780,47780,3.02,3.17,1000,1000,7969204,1.86,9.01,117.194176,3.07006,3.606005,0.0,0.0,USD,-726798,0.0,1406975,2521900,136324,183004,1690761600,1693440000,0.0541,0.11,0.0705,2.863,1.1037374,1656547200,1688083200,1680220800,-19968000,-22.14,-16.1,2:3,1586908800,-10.688,0.038,NCM,EQUITY,BNTC,BNTC,Benitec Biopharma Inc.,Benitec Biopharma Inc.,1403616600,America/New_York,EDT,-14400000,3.16,68.0,68.0,68.0,68.0,2.0,buy,1,6551000,3.98,-19148000,623000,2.095,2.345,68000,13.219,0.062,-1.3173399,-3.26461,64000,-10651000,-18772000,0.125,0.86765,0.0,-283.36765,USD,
1,3940 Trust Way,Hayward,CA,94545,United States,510 780 0819,https://benitec.com,Biotechnology,Healthcare,"Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.",18,"{'maxAge': 1, 'name': 'Ms. Megan Joan Boston BComm, CA, Dip., GAICD', 'age': 50, 'title': 'Exec. Director', 'yearBorn': 1972, 'fiscalYear': 2023, 'totalPay': 322240, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,2.91,2.96,2.96,3.17,2.91,2.96,2.96,3.17,0.0,1.018672,-0.1962733,38245,38245,804526,47780,47780,3.02,3.17,1000,1000,7969204,1.86,9.01,117.194176,3.07006,3.606005,0.0,0.0,USD,-726798,0.0,1406975,2521900,136324,183004,1690761600,1693440000,0.0541,0.11,0.0705,2.863,1.1037374,1656547200,1688083200,1680220800,-19968000,-22.14,-16.1,2:3,1586908800,-10.688,0.038,NCM,EQUITY,BNTC,BNTC,Benitec Biopharma Inc.,Benitec Biopharma Inc.,1403616600,America/New_York,EDT,-14400000,3.16,68.0,68.0,68.0,68.0,2.0,buy,1,6551000,3.98,-19148000,623000,2.095,2.345,68000,13.219,0.062,-1.3173399,-3.26461,64000,-10651000,-18772000,0.125,0.86765,0.0,-283.36765,USD,
2,3940 Trust Way,Hayward,CA,94545,United States,510 780 0819,https://benitec.com,Biotechnology,Healthcare,"Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.",18,"{'maxAge': 1, 'name': 'Dr. Michael  Graham', 'title': 'Head of Discovery & Founding Scientist', 'fiscalYear': 2012, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,2.91,2.96,2.96,3.17,2.91,2.96,2.96,3.17,0.0,1.018672,-0.1962733,38245,38245,804526,47780,47780,3.02,3.17,1000,1000,7969204,1.86,9.01,117.194176,3.07006,3.606005,0.0,0.0,USD,-726798,0.0,1406975,2521900,136324,183004,1690761600,1693440000,0.0541,0.11,0.0705,2.863,1.1037374,1656547200,1688083200,1680220800,-19968000,-22.14,-16.1,2:3,1586908800,-10.688,0.038,NCM,EQUITY,BNTC,BNTC,Benitec Biopharma Inc.,Benitec Biopharma Inc.,1403616600,America/New_York,EDT,-14400000,3.16,68.0,68.0,68.0,68.0,2.0,buy,1,6551000,3.98,-19148000,623000,2.095,2.345,68000,13.219,0.062,-1.3173399,-3.26461,64000,-10651000,-18772000,0.125,0.86765,0.0,-283.36765,USD,
3,3940 Trust Way,Hayward,CA,94545,United States,510 780 0819,https://benitec.com,Biotechnology,Healthcare,"Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.",18,"{'maxAge': 1, 'name': 'Dr. Claudia  Kloth', 'title': 'Sr. VP of Manufacturing', 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,2.91,2.96,2.96,3.17,2.91,2.96,2.96,3.17,0.0,1.018672,-0.1962733,38245,38245,804526,47780,47780,3.02,3.17,1000,1000,7969204,1.86,9.01,117.194176,3.07006,3.606005,0.0,0.0,USD,-726798,0.0,1406975,2521900,136324,183004,1690761600,1693440000,0.0541,0.11,0.0705,2.863,1.1037374,1656547200,1688083200,1680220800,-19968000,-22.14,-16.1,2:3,1586908800,-10.688,0.038,NCM,EQUITY,BNTC,BNTC,Benitec Biopharma Inc.,Benitec Biopharma Inc.,1403616600,America/New_York,EDT,-14400000,3.16,68.0,68.0,68.0,68.0,2.0,buy,1,6551000,3.98,-19148000,623000,2.095,2.345,68000,13.219,0.062,-1.3173399,-3.26461,64000,-10651000,-18772000,0.125,0.86765,0.0,-283.36765,USD,
